Scientific Frontline: Extended "At a Glance" Summary: Rituximab and T Cells in Kidney Disease
The Core Concept: Rituximab (RTX), an intravenous drug primarily known for depleting B cells, has been found to also trigger positive metabolic changes in T cells, specifically improving energy production and lowering cellular stress in patients with nephrotic syndrome who respond favorably to the treatment.
Key Distinction/Mechanism: While RTX's established mechanism is the elimination of B cells, its effectiveness in treating minimal change disease (MCD) is now linked to downstream effects on T cells. In responders, the depletion of B cells reduces T-cell exhaustion, enhances mitochondrial energy metabolism, and lowers reactive oxygen species (ROS) levels, a sequence of events largely absent in non-responders.
Origin/History: RTX has been utilized to treat steroid-dependent nephrotic syndrome, but its mechanism beyond B-cell depletion remained unclear. In Japan, RTX was recently approved for adult health insurance coverage in June 2026, following off-label use and clinical observations conducted at Nagoya University between 2018 and 2022.
Major Frameworks/Components:
- Minimal Change Disease (MCD): A form of nephrotic syndrome where immune system dysregulation damages specialized kidney filtering cells, called podocytes, without causing structural damage visible under standard microscopic examination.
- B-Cell and T-Cell Crosstalk: The fundamental communication pathway between these two immune cell types, which becomes abnormal in MCD and is subsequently modulated by RTX treatment.
- Oxidative Stress Reduction: The mechanism by which RTX lowers elevated levels of reactive oxygen species (ROS) in T cells, preventing the molecular damage and functional degradation associated with cellular exhaustion.
- CD4⁺ Cytotoxic T Cells: A specific subset of T cells that demonstrates significantly reduced exhaustion and improved energy metabolism following successful RTX treatment.
.png)












